c-Src inhibition improves cardiovascular function but not remodeling or fibrosis in Ang II-induced hypertension by Callera, Glaucia E. et al.
 
 
 
 
Callera, G. E., Antunes, T. T., He, Y., Montezano, A. C., Yogi, A., Savoia, 
C., and Touyz, R. M. (2016) c-Src inhibition improves cardiovascular 
function but not remodeling or fibrosis in Ang II-induced hypertension. 
Hypertension, 68(5), pp. 1179-1190. 
(doi:10.1161/HYPERTENSIONAHA.116.07699) 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
 
 
 
http://eprints.gla.ac.uk/122659/ 
     
 
 
 
 
 
 
Deposited on: 14 September 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
 
 
1 
HYPE201607699R 
c-Src inhibition improves cardiovascular function but not remodeling or fibrosis  
in Ang II-induced hypertension 
 
Glaucia E Callera PhD1, Tayze T Antunes PhD1, Ying He MSc1, Augusto C Montezano PhD1,2, 
Alvaro Yogi PhD1, Carmine Savoia MD3, Rhian M Touyz MD, PhD1,2. 
1Kidney Research Centre, Ottawa Hospital Research Institute, University of 
Ottawa, Ontario, Canada; 2Institute of Cardiovascular and Medical Sciences, University of 
Glasgow, UK; 3Clinical and Molecular Medicine Department, Cardiology Unit, Sapienza 
University of Rome, Rome, Italy. 
 
Running title: Role of c-Src in hypertension 
Word count: Abstract:250; Text:5996 
 
To whom correspondence should be addressed: 
Rhian M Touyz MD, PhD 
Institute of Cardiovascular and Medical Sciences, 
BHF Glasgow Cardiovascular Research Centre,  
University of Glasgow, 
126 University Place, Glasgow, G12 8TA, 
Phone: + 44 (0)141 330 7775/7774; Fax: + 44 (0)141 330-3360, 
Email: rhian.touyz@glasgow.ac.uk.  
 
 
2 
Abstract 
c-Src plays an important role in Ang II signaling. Whether this member of the Src family kinases 
is involved in the development of Ang II-induced hypertension and associated cardiovascular 
damage in vivo remains unknown. Here we studied Ang II-infused (400ng/Kg/min) mice in 
which c-Src was partially deleted (c-Src+/-) and in wild-type (WT, c-Src+/+) mice treated with a c-
Src inhibitor (CGP077675(25mg/Kg/day)). Ang II increased blood pressure and induced 
endothelial dysfunction in WT mice, responses that were ameliorated in c-Src+/- and 
CGP077675-treated mice. Vascular wall thickness and cross-sectional area (CSA) were similarly 
increased by Ang II in WT and c-Src+/- mice. CGP077675 further increased CSA in hypertensive 
mice. Cardiac dysfunction (ejection fraction, fractional shortening) in Ang II-infused WT mice 
was normalized in c-Src+/- mice. Increased oxidative stress (plasma TBARS, H2O2 and vascular 
superoxide generation) in Ang II-infused WT mice, was attenuated in c-Src-deficient and 
CGP077675-treated mice. Hyperactivation of vascular c-Src, ERK1/2 and JNK in hypertensive 
mice was normalized in CGP077675-treated and c-Src+/- mice. Vascular fibronectin was 
increased by Ang II in all groups and further augmented by CGP077675. Cardiac fibrosis and 
inflammation induced by Ang II were amplified in c-Src+/- and CGP-treated mice. Our data 
indicate that while c-Src downregulation attenuates development of hypertension, improves 
endothelial and cardiac function, reduces oxidative stress and normalizes vascular signaling, it 
has little beneficial effect on fibrosis. These findings suggest a divergent role for c-Src in Ang II-
dependent hypertension, where c-Src may be more important in regulating redox-sensitive 
cardiac and vascular function than fibrosis and remodeling.  
Key words: c-Src, angiotensin II, oxidative stress, hypertension, CGP077675, endothelial 
dysfunction.  
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Introduction 
Hypertension is associated with vascular damage characterized by impaired endothelial function, 
and arterial remodeling (1,2). Many factors underlie these processes, including angiotensin II 
(Ang II), a particularly important vasoactive peptide in human and experimental hypertension. 
Ang II regulates vascular function and structure by activating complex signaling pathways 
inducing contraction, cell growth, inflammation and fibrosis (3,4). Common to these processes is 
generation of reactive oxygen species (ROS), including superoxide anion and hydrogen peroxide 
(H2O2), and activation of redox-sensitive kinases (5,6). ROS function as intracellular second 
messengers to stimulate mitogen-activated protein kinases (MAPKs), tyrosine kinases and 
transcription factors, and inactivate protein tyrosine phosphatases (7,8). ROS also increase 
intracellular calcium and activate pro-inflammatory transcription factors (9,10). NADPH 
oxidases (Nox), the major source of ROS in the vasculature, are tightly regulated by Ang II in 
vitro and in vivo (11-13).  Mechanisms linking Ang II to Nox and upstream signaling kinases in 
vascular cells have received considerable attention (14,15). Of particular importance in the 
vasculature is c-Src, a member of the Src kinase family of non-receptor tyrosine kinases, key 
proximal regulators of Nox-driven superoxide anion generation and MAPK activation (16-18).  
Src family protein kinases are proto-oncogenes involved in cell morphology, motility, 
proliferation and survival (19,20). There are 11 members of the Src-family in humans, of which 
c-Src, Fyn, and Yes are ubiquitously expressed. The 60-kDa c-Src, the prototype, is highly 
expressed in the vasculature, involved in redox signaling associated with vascular function, and 
rapidly activated by vasoactive agents, including Ang II (21,22). We previously reported that c-
Src plays a major role in Ang II signaling (21-23). In vascular smooth muscle cells (VSMCs) 
from human resistance arteries, Ang II induces c-Src phosphorylation to produce superoxide 
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anion via Nox activation (24-26). Of clinical relevance, our studies demonstrated the 
contribution of c-Src in molecular and cellular processes underlying Ang II-mediated vascular 
changes that occur in human hypertension (24-27). In further support of a role for Src kinases in 
Ang II-dependent hypertension, Bo Qin and Zhou (28) demonstrated that pharmacological 
inhibition of Src family kinases prevented development of hypertension and reduced vascular 
smooth muscle myosin light chain phosphorylation in Ang II-infused mice. However, to our 
knowledge, it still unclear whether c-Src is specifically implicated. Moreover, mechanisms 
whereby c-Src influences cardiovascular function in vivo remain to be elucidated.  
In the present in vivo study, we focused on c-Src as a major player in vascular injury and target 
organ damage in Ang II-induced hypertension. We also explored putative molecular 
mechanisms, specifically ROS, pro-inflammatory and pro-fibrotic signaling pathways, whereby 
c-Src regulates cardiovascular function in hypertension. 
Methods 
See supplemental text  
Animals 
Genetic and pharmacological strategies were used to downregulate c-Src in mice. Firstly, we 
studied wild-type (WT) (c-Src+/+) and heterozygous (c-Src+/-) male mice (29) infused with Ang II 
(400 ng/kg/min,10-12 days). c-Src-/- mice have osteopetrosis with poor survival and hence were 
not studied. In some experiments we infused norepinephrine (NE; 3.8 µg/Kg/min) to assess 
whether c-Src effects are Ang II-specific or generalized. Secondly, we used a pharmacological 
approach to inhibit c-Src. Ang II-infused WT mice received daily injections of a c-Src inhibitor, 
CGP077675 (25 mg/Kg/day,7 days) (30), started 5 days after initiation of Ang II infusion. At 
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study-end, plasma, aorta, mesenteric arteries and heart were collected. Systolic BP (SBP) was 
assessed by tail-cuff plethysmography and telemetry (11,31,). 
Plasma Biochemistry  
Plasma glucose, triglycerides, and cholesterol were determined by automated analyzer  
Echocardiography  
Cardiac geometry and function were evaluated by echocardiography (32). 
Assessment of vascular function, structure and mechanics 
Second order branches of the superior mesenteric artery were mounted in a pressure myograph 
and function, structure and mechanics studied (33). 
ROS assessment 
Vascular ROS generation was measured by lucigenin chemiluminescence and dihydroethidium 
fluorescence. Systemic oxidative stress was determined by quantifying plasma thiobarbituric 
acid-reactive substances (TBARS) levels and by amplex red (7,11). 
Western blotting 
Vascular protein was extracted and immunoblotted as described (7).  
Histological and immunohistochemical analyses 
Heart and aortic tissues were stained with Masson’s trichrome or Sirius Red, and macrophages, 
labelled with CD68-antibody. 
Statistics  
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Data are presented as means±SEM. Groups were compared using one-way ANOVA, two-way 
ANOVA or t-test as appropriate. P<0.05 was significant. 
Results 
Mouse characteristics  
Table S1 demonstrates morphological and metabolic characteristics. Ang II increased heart mass 
in WT but not in c-Src+/- mice. Metabolic parameters were similar between groups (Table S2).  
Ang II-induced cardiac dysfunction is ameliorated in c-Src+/- mice  
Ang II-infused WT mice exhibited reduced fractional shortening and increased IVSd and 
LVPWd (Table S3).  
Ang II-induced hypertension is blunted in c-Src-deficient mice 
Ang II increased SBP in WT mice (Fig.1A). In c-Src+/- mice, Ang II-induced BP increase was 
attenuated (Fig.1A). To evaluate whether c-Src effects are specific for Ang II, we also examined 
NE-induced pressor effects in c-Src-deficient mice. NE increased in SBP in both c-Src+/+ and c-
Src+/- mice, with similar maximal responses between groups (Fig.1B).  
CGP077675 normalises blood pressure in Ang II-infused mice 
In another series of experiments, c-Src+/+ mice were infused with Ang II in the absence and 
presence of CGP077675. Ang II-induced increase in SBP was reduced by CGP077675 (Fig.1C). 
Within 5 days of CGP077675, SBP was normalised to levels in vehicle-treated mice. BP 
responses observed by tail-cuff measurement were similar to those measured by telemetry 
(Fig.S1) 
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Endothelial dysfunction is ameliorated by c-Src downregulation in Ang II-induced 
hypertension 
Ach-induced vasodilation was blunted in Ang II-infused c-Src+/+ mice, with maximal 
vasodilatory responses of 30% versus 70% in vehicle-infused counterparts. In c-Src+/- mice, Ang 
II-induced maximal vasodilation was improved to 49.9% versus Ang II-infused controls (Fig.1D, 
Table S3). Ang II did not influence ACh-induced relaxation in c-Src+/- mice versus vehicle-
infused c-Src+/- mice. In CGP077675-treated mice, Ach-mediated vasodilation was improved 
versus untreated mice (Fig.1D, Table S4).  
SNP-induced endothelium-independent relaxation in Ang II-infused mice was unaltered 
(Fig.S2A) and responses to SNP were unaffected by CGP077675 (Fig.S2B). 
Contractile responses in c-Src deficient mice 
Contractile responses were similar in vehicle- and Ang II-infused mice (WT and c-Src+/- ) 
(Figs.S3A, Fig S3B).  CGP077675 did not influence contractile responses (Fig S3A).  
c-Src and small vessel structure  
Morphologic parameters in small mesenteric arteries were evaluated at progressive increases in 
intraluminal pressure (Fig.S4). Mesenteric arteries from vehicle-infused c-Src+/+ and c-Src+/- 
mice exhibited similar media thickness, lumen diameter, media:lumen ratio and cross sectional 
area. Ang II-infused c-Src+/+ mice displayed increased media thickness (Fig.2A) without changes 
in lumen diameter (Fig.2B), resulting in a higher media:lumen ratio (Fig.2C) versus c-Src+/+ 
vehicle-infused mice. Ang II did not alter the cross sectional area (Fig.2D), although a tendency 
towards an increase was observed. In CGP077675-treated Ang II-infused mice, media thickness, 
media:lumen ratio and cross-sectional area were significantly greater than that in vehicle-treated 
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control mice (Figs.2B-D). Arteries from Ang II-infused c-Src+/- mice exhibited increased media 
thickness and media:lumen ratio (Figs.2E,2G), with no changes in lumen diameter or cross 
sectional area (Figs.2F,2H).  
c-Src and vascular mechanics  
Mechanical properties were evaluated at progressive increases in intraluminal pressure (Fig. S5). 
Mesenteric arteries from Ang II-infused c-Src+/+ and c-Src+/- mice exhibited reduced mechanical 
stress versus vehicle-infused counterparts in response to stepwise increments of intraluminal 
pressure. No additional shift was observed in the mechanical stress curves from the CGP077675-
treated Ang II-infused mice.  
c-Src and aortic structure 
Photomicrographs of Masson’s trichrome-stained cross-sections of thoracic aorta showed a 
significant increase in the media thickness with Ang II infusion in c-Src+/+ and c-Src+/- mice 
(Fig.3). Aortic thickening is evidenced by irregularities in the pattern and the distances between 
each concentric elastic lamina intermingled with smooth muscle cell layers (Fig.3A). 
Morphometric quantitative analysis showed that Ang II effects were was attenuated by 
CGP077675 but not by c-Src deficiency (Fig.3B). Slight thickening of the adventitial layer with 
perivascular fibrosis surrounding the vessel wall was also observed in some Ang II-infused mice. 
c-Src inhibition attenuates vascular and systemic oxidative stress in Ang II-induced 
hypertension 
DHE fluorescence images show increased ROS generation in aortas from Ang II-infused mice, 
an effect attenuated by CGP077675 and c-Src deficiency (Fig.4A). Lucigenin-derived 
luminescence was increased in both aorta (Fig.4B) and mesenteric arteries (Fig.4C) from Ang II-
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infused c-Src+/+ mice. CGP077675 reduced the increase of superoxide generation. Ang II 
infusion did not induce superoxide production vessels from c-Src+/- mice. NE did not induce 
activation of vascular NADPH oxidase (Fig.4B). Plasma TBARS levels (products of lipid 
peroxidation), measured as an index of systemic oxidative stress, were higher in Ang II–infused 
c-Src+/+ mice versus vehicle-treated counterparts (Fig.4D). This increase was reduced by 
CGP077675. Ang II did not increase plasma TBARS levels in c-Src +/- mice. Ang II–infused c-
Src+/+ mice displayed increased plasma levels of H2O2 versus vehicle-infused Src+/+ mice 
(Fig.4E). CGP077675 reduced plasma H2O2 levels in Ang II–infused mice. Plasma H2O2 levels 
were similar in Src +/- mice infused with either vehicle or Ang II. 
c-Src, eNOS, eNOS [Ser1178] phosphorylation and caveolin-1 in Ang II-infused mice 
Underlying molecular mechanisms whereby c-Src influences endothelium-dependent 
vasodilation were investigated by probing eNOS expression and phosphorylation. No differences 
were observed in eNOS protein expression (Fig.S6A) and phosphorylation at Ser1178 (activation 
residue) (Fig.S6B) in arteries from c-Src+/+ and c-Src+/- mice treated with vehicle or Ang II. 
CGP077675 did not influence eNOS. Expression of caveolin-1, a negative regulator of eNOS, 
was increased in Ang II-infused c-Src+/+ mice, effects that were inhibited by CGP077675 
(Fig.S6C). Caveolin-1 was unaffected by Ang II in c-Src+/- mice versus vehicle-infused 
counterparts. Levels of urinary nitrite/nitrate (marker of systemic NO production), was not 
different between groups (Fig.S6D). 
c-Src expression and phosphorylation  
Total c-Src protein content was reduced in tissues from c-Src+/- mice (Fig.S7A) and was not 
influenced by CGP077675 (Figs.S7B,S7C). Ang II-induced vascular c-Src phosphorylation 
 
 
10 
(Figs.5A,S8A) in WT mice was abrogated by CGP077675. Ang II failed to induce c-Src 
phosphorylation in vessels from c-Src+/- mice. 
c-Src differentially regulates phosphorylation of vascular MAPKs in Ang II-induced 
hypertension 
ERK1/2 phosphorylation was increased in mesenteric arteries of Ang II-infused c-Src+/+ mice 
(Fig.5B). CGP077675 reduced ERK1/2 phosphorylation below levels observed in vehicle-
infused c-Src+/+ mice. ERK1/2 phosphorylation was lower in Ang II-infused c-Src+/- mice 
compared with vehicle-infused counterparts. In aorta Ang II-induced ERK1/2 phosphorylation 
was blunted by c-Src inhibition (Fig.S8B). In mesenteric arteries from c-Src+/+ and c-Src+/- mice, 
p38MAPK phosphorylation was unaffected by Ang II. CGP077675 did not influence p38MAPK 
in Ang II-infused mice (Fig.5C). Ang II increased vascular JNK phosphorylation, an effect that 
was inhibited by CGP077675. Ang II failed to increase JNK phosphorylation in c-Src+/- mice 
(Fig.5D). 
Norepinephrine (NE) does not induce c-Src or ERK1/2 phosphorylation  
The effect of NE infusion on c-Src and ERK1/2 phosphorylation was evaluated in aortas from c-
Src+/+ and c-Src+/- mice (Fig.S9). NE had no effect on vascular c-Src or ERK1/2 phosphorylation.  
Molecular markers of inflammation and fibrosis in Ang II-induced hypertension. 
Pro-inflammatory pathways were investigated by probing for COX2, VCAM-1 and PAI-1. As 
shown in Figure 6A, COX2 was increased by Ang II,  effects that were inhibited by CGP077675. 
COX2 expression was similar in vehicle- and Ang II-treated c-Src+/- mice. Ang II failed to 
increase expression of pro-inflammatory molecules in c-Src+/- mice. Expression of VCAM-1 
(Fig.6B) was not altered by Ang II, although CGP077675 reduced basal expression of the 
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adhesion molecule. There were no differences in VCAM-1 expression in c-Src-deficient mice 
infused with vehicle or Ang II. PAI-1 expression was not influenced by either CGP077675 or c-
Src deficiency (Fig.6C). Figure 6D shows that vascular fibronectin expression is increased by 
Ang II in Src+/+ and c-Src+/- mice, effects that were augmented by CGP077675 in c-Src+/+ mice. 
Increased fibronectin expression was also evident in Ang II-infused c-Src+/- mice versus control 
counterparts  
Molecular markers of growth and contraction are unaltered by c-Src inhibition or 
deficiency. 
In mesenteric arteries from c-Src +/+ mice, PCNA expression, a molecular marker of cell growth, 
was unaffected by Ang II infusion alone or in association with CGP077675 treatment 
(Fig.S10A). PCNA expression was similar in c-Src +/- mice infused with vehicle or Ang II. In 
mesenteric arteries from c-Src+/+ and c-Src+/- mice, phosphorylation of MLC, an index of 
vascular contraction, was unaffected by Ang II infusion (Fig.S10B). CGP077675 or c-Src 
deficiency did not influence phosphorylation of MLC in Ang II-infused mice.  
Histopathology of the heart 
Hypertension-associated cardiac damage was also assessed by evaluating cardiac collagen 
accumulation and interstitial fibrosis by Sirius Red and Masson’s trichrome staining respectively. 
Representative heart sections are shown in Figure S11. Hearts from Ang II-infused mice 
displayed excessive deposition of collagen with fibrotic areas and positive staining for CD68, 
identifying the presence of mononuclear inflammatory cell infiltrate. Pharmacological inhibition 
of c-Src exacerbated the fibrotic and inflammatory processes induced by Ang II, since hearts 
from mice treated with CGP077675 stained highly positive for CD68 and presented more 
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extensive areas of collagen accumulation and fibrosis. Increased collagen deposition and fibrosis 
were also evident in Ang II-infused c-Src+/- mice. 
Discussion 
Major finding from the present study demonstrate that pharmacological and genetic inactivation 
of c-Src prevents development of hypertension in Ang II-infused mice. Endothelial and cardiac 
dysfunction were ameliorated by c-Src inhibition, processes associated with reduced oxidative 
stress and decreased activation of ERK1/2, JNK and pro-inflammatory signaling pathways. 
Whereas vascular functional responses were ameliorated by c-Src downregulation, Ang II-
induced cardiovascular remodeling and fibrosis were amplified by c-Src inactivation or 
deficiency, as evidenced by increased vascular media thickness, cross-sectional area and 
fibronectin expression in resistance and conduit arteries. Similar trends were evident in the hearts 
of Ang II-induced hypertensive mice where cardiac fibrosis was also exaggerated by 
CGP077675 or c-Src deficiency. These findings suggest that while c-Src inhibition prevents 
development of hypertension, improves endothelial and cardiac function, reduces oxidative stress 
and normalizes vascular signaling, it has little beneficial effect on cardiovascular remodeling or 
fibrosis. Our study suggests a divergent role for c-Src in Ang II-dependent hypertension, where 
c-Src may be more important in regulating redox-sensitive cardiac and vascular function rather 
than processes associated with cardiovascular fibrosis and structure. These novel insights 
underscore the complex role of c-Src in Ang II-induced hypertension and suggest that c-Src 
inhibition as a potential therapeutic modality should be considered with caution, because while it 
improves endothelial and cardiac function, it may aggravate cardiovascular fibrosis.  
Ang II, an important vasoactive hormone, mediates effects through multiple complex signaling 
pathways that regulate vascular cell contraction/relaxation, growth, apoptosis, senescence, 
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fibrosis, and inflammation, processes involved in the regulation of vascular function and 
structure (8-11).  Central to these events is c-Src and ROS, which are tightly interlinked (21-23).  
We previously demonstrated in human and rodent VSMCs that Ang II-induced increase in 
[Ca2+]i, phosphorylation of MAPKs, regulation of RhoA/Rho kinase and activation of Nox are c-
Src-dependent (23-25). While extensive in vitro evidence indicates a critical role for c-Src in 
Ang II signaling in cardiovascular cells, the pathophysiological significance of c-Src in 
hypertension and associated cardiovascular injury, in vivo, requires further investigation. 
Using pharmacological and genetic approaches to inhibit c-Src activation, we interrogated the 
role of this non-receptor tyrosine kinase in the development of hypertension. Ang II induced a 
significant increase in BP in c-Src+/+ mice, responses that were associated with increased 
activation of vascular c-Src. These effects were inhibited when c-Src activity was 
downregulated. To support these findings, CGP077675, a pharmacological c-Src inhibitor of the 
pyrrolopyrimidine class that acts on the autophosphorylation site of the tyrosine kinase 
suppressing its activity (30) exhibited anti-hypertensive effects in Ang II-infused mice. Similar 
results were reported for SU6656, a non-specific Src family kinase inhibitor, (28). c-Src-
associated pressor actions seem to be highly regulated by specific vasoactive agents, since NE-
induced hypertension was unaffected by c-Src-deficiency.  
The BP lowering effect of CGP077675 was rapid, occurring within 2 days after treatment, 
indicating that c-Src inhibitory effects likely occur through increased endothelium-dependent 
vasodilation, typically associated with acute BP changes. In support of this the reduced Ach-
induced vasorelaxation in c-Src+/+ mice was improved in CGP077675-treated mice, indicating 
vasoprotection by c-Src inhibition. Molecular processes underlying these actions may relate to 
oxidative inactivation of NO as previously reported (34), and is supported by our findings of no 
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change in eNOS phosphorylation with concomitant increase in ROS production. It may also be 
possible that c-Src influences eNOS indirectly by upregulating caveolin-1, a negative modulator 
of eNOS (35). This may be especially important in the endothelium, which is rich in caveolin-1 
and eNOS (36). CGP077675 normalized caveolin-1 expression in Ang II-infused mice with 
associated improvement in endothelial function and blood pressure reduction. Our findings differ 
to those previously reported where c-Src was found to induce activation of eNOS through PI3-
kinase/Akt. However, those studies were performed in cultured endothelial cells (37).  
Ang II-induced hypertension was associated with increased systemic and vascular ROS 
generation as evidenced by increased levels of plasma TBARS and H2O2 and enhanced vascular 
NADPHoxidase-derived superoxide production. These findings confirm previous studies 
demonstrating an important pathophysiological role for oxidative stress in the development of 
hypertension and associated vascular dysfunction. CGP077675 normalized redox status in Ang 
II-infused mice, indicating a role for c-Src in oxidative stress in hypertension. Since endothelial 
function is regulated not only by NO-dependent mechanisms but also by redox-sensitive 
pathways, the improved endothelial function in CGP077675-treated mice may relate, at least in 
part, to reduced oxidative stress (34). We previously demonstrated a close interaction between 
Nox, ROS and c-Src in human and rat VSMCs and found that c-Src was both upstream and 
downstream of Nox (16,21-23). We showed that this occurs through c-Src-induced 
phosphorylation of p47phox and increased abundance of NADPHoxidase subunits (16). The c-
Src-ROS link in VSMCs has recently been highlighted (38) and is increasingly being recognized 
as a feedforward loop whereby oxidative stress is amplified when c-Src is activated. Interrupting 
this loop by inhibiting c-Src dampens activation of downstream redox signaling including 
MAPK and pro-inflammatory transcription factors. This is evidenced here in our in vivo study 
 
 
15 
where increased ROS generation, MAPK phosphorylation and enhanced COX2 expression in 
hypertensive mice, were normalized or attenuated by c-Src downregulation. c-Src seems to be 
especially important in Ang II-induced ERK1/2 activation, because c-Src inhibition reduced 
phosphorylation of ERK1/2 below basal levels. The critical role of c-Src in these events is 
underscored by the fact that even partial reduction of c-Src (in heterozygous mice) is enough to 
normalize signaling in Ang II-infused mice.  
c-Src regulatory effects of Ang II are not generalized phenomena, because phosphorylation of 
p38MAPK was not altered by c-Src deficiency. These findings are in contrast to our earlier 
studies in aldosterone-treated vascular smooth muscle cells, where we found that p38MAPK 
activation is c-Src-sensitive (39). Hence, c-Src actions are agonist/receptor-sensitive, highly 
regulated and target protein-specific.  
At the vascular level, hypertension is characterized not only by endothelial dysfunction, but also 
by vascular structural (remodeling) and mechanical changes (40,41). In particular small arteries 
in hypertension undergo inward eutrophic remodeling and/or hypertrophic remodeling with 
associated impaired mechanical properties (2,40). Increased collagen deposition, fracturing of 
elastin, calcium deposition, proliferation, rearrangement and hypertrophy of VSMCs and 
inflammation contribute to these processes (40-42). Mechanically, vessels become stiffer and 
less distensible. In hypertension vascular remodeling has an important Ang II-dependent 
component as evidenced by clinical investigations demonstrating that ACE inhibition or AT1 
receptor blockers prevented or reversed structural and mechanical changes (42-44). In our study, 
significant vascular alterations were observed in both resistance and conduit arteries. Small 
mesenteric arteries of Ang II-infused c-Src+/+ mice exhibited increased media thickness, cross-
sectional area and vascular stiffness, responses that also present in c-Src+/- mice. These findings 
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suggest that Ang II-induced remodeling may be independent of c-Src activation. In aorta, media 
thickness was also increased by Ang II in both c-Src+/+ and c-Src+/- mice. CGP077675 did not 
improve structural and mechanical changes and in fact hypertrophy was exaggerated in small 
arteries. However, differential effects were observed in aorta, where CGP077675 prevented the 
increase in media thickness. At the molecular level, vascular fibronectin expression was similarly 
increased by Ang II in c-Src+/+ and c-Src-deficient mice. Moreover CGP077675 exacerbated 
fibronectin expression in Ang II-infused mice. To further support our findings that Ang II-
induced remodeling is likely c-Src independent, we observed that collagen deposition, fibrosis 
and inflammation were variably increased in hearts from c-Src-deficient mice and in mice treated 
with CGP077675. These findings suggest that c-Src may not play a major role in cardiovascular 
growth or fibrosis and may not contribute significantly to structural changes elicited by Ang II, at 
least in the model studied here.  
PCNA, a marker of cell proliferation was not significantly altered in c-Src+/- or CGP077675-
treated mice. Reasons for the additional trophic and pro-fibrotic effects of CGP077675 are 
unclear, but may relate to effects on cell cycle regulators other than PCNA, since expression and 
activity of the cyclin-dependent kinase (CDK)-inhibitor p21WAF1/CIP1 are reduced by the c-
Src inhibitor resulting in cell cycle progression (45).  Moreover we can not exclude the 
possibility that CGP077675 may have some non-specific effects, since it can also inhibit other 
Src isoforms (46).  
Perspectives 
Our results provide in vivo evidence to show that c-Src plays an important role in the 
pathophysiology of Ang II-dependent hypertension through processes that involve ROS and 
MAPK. While vascular and cardiac functional alterations and redox-dependent processes are c-
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Src-dependent, arterial remodeling and cardiac fibrosis are c-Src-independent. Although c-Src 
may be an interesting potential therapeutic target to reduce blood pressure and improve 
cardiovascular function, caution is warranted regarding the possible pro-fibrotic cardiovascular 
effects of c-Src inhibition.  
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Novelty and significance 
What is new? 
• Genetic and pharmacological inhibition of c-Src reduces blood pressure and ameliorates 
endothelial and cardiac dysfunction  in Ang II-induced hypertension. 
• c-Src effects may be Ang II-specific, because NE-induced hypertension was unaffected by 
c-Src inhibition. 
• Ang II-induced cardiovascular fibrosis and remodelling are not protected by c-Src inhibition. 
What is relevant?  
• In Ang II-induced hypertension c-Src plays a role in functional but not structural changes in 
the cardiovascular system.  
• c-Src may have differential cardiovascular effects, both protective and injurious, in Ang II-
induced hypertension. 
Summary  
• c-Src may be more important in regulating redox-sensitive cardiovascular function than 
fibrosis and remodeling.  
• While inhibition of c-Src may be an attractive strategy to reduce blood pressure, improve 
endothelial function and prevent target organ damage, caution is warranted because of the 
potential pro-fibrotic consequences of c-Src inhibition.   
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Figure Legends 
Figure 1. c-Src plays a role in Ang II-induced hypertension and vascular dysfunction. Time 
course of SBP in: (A) c-Src+/+ and c-Src+/- mice infused with vehicle or Ang II; (B) c-Src+/+ and 
c-Src+/- mice infused with vehicle or NE; (C) c-Src+/+ mice infused with vehicle or Ang II, with 
the arrow indicating the time of CGP077675 treatment. (D) c-Src inhibition improves 
endothelium-dependent vasodilation in Ang II-infused mice. Concentration-response curves to 
ACh (1nmol/L-100 µmol/L) were performed in endothelium-intact arteries. Results are 
mean±SEM of 5-15/group. *P< 0.05 vs. vehicle-infused counterparts, P< 0.05 CGP077675-
treated Ang II-infused c-Src+/+ mice vs. Ang II-infused c-Src+/+ mice, **P< 0.05 Ang II-infused 
c-Src+/- mice, ++P <0.05 vs. Ang II-infused c-Src+/+ mice. 
Figure 2. c-Src inhibition influences structural properties of mesenteric resistance arteries 
in Ang II-infused mice. Small mesenteric arteries were mounted in a pressure myograph. 
Measurements of media and lumen were taken at stepwise increments of luminal pressure (3-140 
mmHg) in zero Ca2+ Krebs solution containing 10 mM EGTA. Line graphs: media, lumen, 
media:lumen ratio, and cross-sectional area (CSA) at increasing luminal pressure in arteries from 
c-Src+/+ (A, B, C, D) and c-Src+/- (E, F, G, H) mice. Results are mean±SEM of 5-11 mice/group. 
*P <0.05 vs. vehicle-infused mice, **P <0.05 vs. Ang II-infused c-Src+/+ mice. 
Figure 3. Effects of CGP077675 and c-Src-deficiency on aortic hypertrophy in Ang II-
induced hypertension. Paraffin-embedded thoracic aorta sections were processed for Masson’s 
trichrome staining. For morphometric analysis in cross-sections of aorta, the wall thickness was 
measured in four regions and values averaged. Upper panels, representative photomicrographs of 
Masson’s trichrome-stained thoracic aorta sections, original magnifications x400. Bar graph, 
 
 
26 
wall thickness of aortic segments. Results are presented as mean±SEM of 5 mice/group *P <0.05 
vs. vehicle-infused c-Src+/+ mice, P <0.05 vs. vehicle-infused c-Src+/- mice. 
Figure 4. c-Src plays a role in Ang II-induced increase in vascular reactive oxygen species 
(ROS) generation. (A) Upper panels, representative images of ROS levels assessed by 
dihydroethidium (DHE) fluorescence in aortic rings. Original magnification, x320. Images are 
representative of five independent experiments. Bar graphs, NADPH-dependent lucigenin-
derived luminescence in homogenates of (B) aorta and (C) mesenteric arteries; (D) plasma 
TBARS levels; (E) plasma H2O2 levels. Values are mean±SEM of 4-12 mice/group. *P <0.05 vs. 
vehicle-infused c-Src+/+ mice, **P <0.05 vs. Ang II-infused c-Src+/+ mice. 
Figure 5. c-Src inhibition influences vascular signaling in Ang II-infused mice. 
Phosphorylation levels of c-Src (A), ERK1/2 (B), p38MAPK (C), and JNK (D) were analyzed in 
mesenteric arteries from vehicle or Ang II-infused c-Src+/+ and c-Src+/- mice, and CGP077675-
treated Ang II-infused c-Src+/+ mice and presented as the a ratio to β-actin. Upper panels, 
representative immunoblots of c-Src [Tyr418], ERK1/2 [Thr202/Tyr204], p38MAPK 
[Thr180/Tyr182], JNK [Thr183/Tyr185], and β-actin. Bar graphs represent mean±SEM of 4-6 
mice/group. *P <0.05 vs. vehicle-infused c-Src+/+ mice, ** P <0.05 vs. Ang II-infused c-Src+/+ 
mice,P <0.05 vs. vehicle-infused c-Src+/- mice. 
Figure 6. c-Src inhibition influences vascular expression of pro-inflammatory and pro-
fibrotic markers. Protein expression levels of COX-2 (A), VCAM-1 (B), PAI (C), and (D) 
fibronectin were analyzed in mesenteric arteries from vehicle or Ang II-infused c-Src+/+ mice, 
and CGP077675-treated Ang II-infused c-Src+/+ mice and presented relative to β-actin or 
GAPDH. Upper panels, representative immunoblots of COX-2, VCAM-1, PAI-1, fibronectin, β-
actin and GAPDH. Bar graphs represent mean±SEM of 4-9 mice/group. *P <0.05 vs. vehicle-
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infused c-Src+/+ mice, ** P <0.05 vs. Ang II-infused c-Src+/+ mice ,P <0.05 vs. vehicle-infused 
c-Src+/- mice. 
